We are monitoring the impact of COVID-19 on Europe Angina Pectoris Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 8024
Share on
Share on

Europe Angina Pectoris Drugs Market By Therapeutic Class ( Beta Blockers, Calcium Antagonists, Anticoagulants, Anti-platelets And Others) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Pulished: February, 2020
ID: 8024
Pages: 145

Europe Angina Pectoris drugs Market was worth USD xx billion in 2018 and estimated to be growing at a CAGR of xx%, to reach USD xx billion by 2023.Angina pectoris refers to the disorder characterised by chest pain due to insufficient blood flow to the heart. It can also be caused due to anaemia, abnormal heart rhythms and heart failure. It Is classified into stable and unstable angina.

Increased prevalence of cardiovascular diseases and rise in the geriatric population are driving the market growth. Increased research and development projects in the healthcare segment and increased healthcare expenditure are further fuelling the market growth. However, the huge investment which goes into developing new drugs is the major factor hampering the growth of the market.

The market for Angina Pectoris drugs is broadly categorized into therapeutic class. By therapeutic class the market is segmented into beta blockers, calcium antagonists, anticoagulants, anti-platelets and others. On the basis of geography, the market is analysed under various regions namely U.K , Germany, Italy, France and Spain. Europe is the second largest market for angina pectoris drugs.

Some of the major companies dominating the market, by their products and services include Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd. and Baxter Healthcare Corporation.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutic class                     

                                5.1.1 Introduction           

                                5.1.2 Beta blockers         

                                5.1.3 Calcium anatagonists          

                                5.1.4 Anticoagulants      

                                5.1.5 Anti platelets         

                                5.1.6 Others      

                                5.1.7  Y-o-Y Growth Analysis, By therapeutic class            

                                5.1.8  Market Attractiveness Analysis, By therapeutic class          

                                5.1.9 Market Share Analysis, By therapeutic class             

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                       By Geographical Area

                                       By therapeutic class

                                6.1.4  Market Attractiveness Analysis     

                                       By Geographical Area

                                       By therapeutic class

                                6.1.5  Market Share Analysis      

                                       By Geographical Area

                                       By therapeutic class

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Anthera Pharmaceuticals                     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Cardium Therapeutics                            

                8.3 Sanofi                           

                8.4 Bayer HealthCare                     

                8.5 Cardeus Pharmaceuticals                     

                8.6 Ark Therapeutics Group plc                 

                8.7 Torrent Pharmaceuticals Limited                       

                8.8 Circ Pharma Limited                

                8.9 Viromed Co. Ltd.                      

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         


                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Therapeutic Class, By Region along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market


  1. Europe Angina Pectoris drugs Market By Therapeutic class, From 2018-2023 ( USD Million )
  2. Europe Beta blockers Market By Region, From 2018-2023 ( USD Million )
  3. Europe Calcium antagonists Market By Region, From 2018-2023 ( USD Million )
  4. Europe Anti coagulants Market By Region, From 2018-2023 ( USD Million )
  5. Europe Anti platelets Market By Region, From 2018-2023 ( USD Million )
  6. Europe Others Market By Region, From 2018-2023 ( USD Million )
  7. U.K. Angina Pectoris drugs Market By Therapeutic class, From 2018-2023 ( USD Million )
  8. Germany Angina Pectoris drugs Market By Therapeutic class, From 2018-2023 ( USD Million )
  9. France Angina Pectoris drugs Market By Therapeutic class, From 2018-2023 ( USD Million )
  10. Italy Angina Pectoris drugs Market By Therapeutic class, From 2018-2023 ( USD Million )
  11. Spain Angina Pectoris drugs Market By Therapeutic class, From 2018-2023 ( USD Million )

Please wait. . . . Your request is being processed


$ 1234 3335

Click for Request Sample